Renal Denervation Market Size- By Technology - Regional Outlook, Competitive Strategies and Segment Forecast to 2034

Description

Renal Denervation Market Introduction and Overview

According to SPER market research, 'Global Renal Denervation Market Size- By Technology - Regional Outlook, Competitive Strategies and Segment Forecast to 2033' state that the Global Renal Denervation Market is predicted to reach 14.32 billion by 2034 with a CAGR of 40.49%.

A catheter-based, minimally invasive method of treating hypertension is renal denervation. Radiofrequency ablation reduces blood pressure by reducing nerve activity by targeting and burning the nerves in the renal arteries. This is typically advised when medicine is ineffective for controlling blood pressure. Using radiofrequency pulses or ultrasound, the nerves along the renal artery wall are ablated to decrease sympathetic activity in the kidneys and lower blood pressure.

Restraints: A significant barrier that could limit patients' access to the drug is the lack of widespread regulatory approval and inconsistent reimbursement procedures. Stricter rules in some places are slowing the adoption of new devices and technology. Furthermore, there is still a lack of long-term efficacy and safety information, which may make medical professionals reluctant to fully embrace renal denervation, even if clinical trials have produced positive results.

Scope of the Report:

Report Metric Details

Market size available for years 2021-2034

Base year considered 2024

Forecast period 2025-2034

Segments covered By Technology.

Regions covered

North America, Asia-Pacific, Latin America, Middle East & Africa and Europe.

Companies Covered Abbott, Ablative Solutions, Inc., Boston Scientific Corporation, Johnson & Johnson Services, Inc., Medtronic, Mercator MedSystems, Inc., Otsuka Medical Devices Co., Ltd., SympleSurgical, Inc., and others.

Renal Denervation Market Segmentation:

By Technology: Based on the Technology, Global Renal Denervation Market is segmented as; Radiofrequency based, Ultrasound based, Micro-Infusion based.

By Region: This research also includes data for North America, Asia-Pacific, Latin America, Middle East & Africa and Europe.

Product Code: MEDE2513

1. Introduction

1.1. Scope of the report
1.2. Market segment analysis

2. Research Methodology

2.1. Research data source
- 2.1.1. Secondary Data
- 2.1.2. Primary Data
- 2.1.3. SPERs internal database
- 2.1.4. Premium insight from KOLs
2.2. Market size estimation
- 2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation

3. Executive Summary

4. Market Dynamics

4.1. Driver, Restraint, Opportunity and Challenges analysis
- 4.1.1. Drivers
- 4.1.2. Restraints
- 4.1.3. Opportunities
- 4.1.4. Challenges

5. Market variable and outlook

5.1. SWOT Analysis
- 5.1.1. Strengths
- 5.1.2. Weaknesses
- 5.1.3. Opportunities
- 5.1.4. Threats
5.2. PESTEL Analysis
- 5.2.1. Political Landscape
- 5.2.2. Economic Landscape
- 5.2.3. Social Landscape
- 5.2.4. Technological Landscape
- 5.2.5. Environmental Landscape
- 5.2.6. Legal Landscape
5.3. PORTERs Five Forces
- 5.3.1. Bargaining power of suppliers
- 5.3.2. Bargaining power of buyers
- 5.3.3. Threat of Substitute
- 5.3.4. Threat of new entrant
- 5.3.5. Competitive rivalry
5.4. Heat Map Analysis

6. Competitive Landscape

6.1. Global Renal Denervation Market Manufacturing Base Distribution, Sales Area, Product Type
6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Renal Denervation Market

7. Global Renal Denervation Market, By Technology (USD Million) 2021-2034

7.1. Radiofrequency based
7.2. Ultrasound based
7.3. Micro-Infusion based

8. Global Renal Denervation Market Forecast, (USD Million) 2021-2034

8.1. Global Renal Denervation Market Size and Market Share

9. Global Renal Denervation Market, By Region, (USD Million) 2021-2034

9.1. Asia-Pacific
- 9.1.1. Australia
- 9.1.2. China
- 9.1.3. India
- 9.1.4. Japan
- 9.1.5. South Korea
- 9.1.6. Rest of Asia-Pacific
9.2. Europe
- 9.2.1. France
- 9.2.2. Germany
- 9.2.3. Italy
- 9.2.4. Spain
- 9.2.5. United Kingdom
- 9.2.6. Rest of Europe
9.3. Middle East and Africa
- 9.3.1. Kingdom of Saudi Arabia
- 9.3.2. United Arab Emirates
- 9.3.3. Qatar
- 9.3.4. South Africa
- 9.3.5. Egypt
- 9.3.6. Morocco
- 9.3.7. Nigeria
- 9.3.8. Rest of Middle-East and Africa
9.4. North America
- 9.4.1. Canada
- 9.4.2. Mexico
- 9.4.3. United States
9.5. Latin America
- 9.5.1. Argentina
- 9.5.2. Brazil
- 9.5.3. Rest of Latin America

10. Company Profile

10.1. Abbott
- 10.1.1. Company details
- 10.1.2. Financial outlook
- 10.1.3. Product summary
- 10.1.4. Recent developments
10.2. Ablative Solutions, Inc.
- 10.2.1. Company details
- 10.2.2. Financial outlook
- 10.2.3. Product summary
- 10.2.4. Recent developments
10.3. Boston Scientific Corporation
- 10.3.1. Company details
- 10.3.2. Financial outlook
- 10.3.3. Product summary
- 10.3.4. Recent developments
10.4. Johnson & Johnson Services, Inc.
- 10.4.1. Company details
- 10.4.2. Financial outlook
- 10.4.3. Product summary
- 10.4.4. Recent developments
10.5. Medtronic
- 10.5.1. Company details
- 10.5.2. Financial outlook
- 10.5.3. Product summary
- 10.5.4. Recent developments
10.6. Mercator MedSystems, Inc.
- 10.6.1. Company details
- 10.6.2. Financial outlook
- 10.6.3. Product summary
- 10.6.4. Recent developments
10.7. Otsuka Medical Devices Co., Ltd.
- 10.7.1. Company details
- 10.7.2. Financial outlook
- 10.7.3. Product summary
- 10.7.4. Recent developments
10.8. SympleSurgical, Inc.
- 10.8.1. Company details
- 10.8.2. Financial outlook
- 10.8.3. Product summary
- 10.8.4. Recent developments
10.9. Others